Physician profile
Christina Ann Fleres
NPI 1750910469
$1,522.61
in general payments reported to CMS, 2019-2025
11 companies · $609 in 2025
The $609 reported for 2025 was more than what 75% of Obesity Medicine (Family Medicine) providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $104 · 2024: $810 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $564.10 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $543.28 | 2023-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $103.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $73.23 | 2023-2025 | Farxiga, Breztri |
| Madrigal Pharmaceuticals | $52.87 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $48.78 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $37.38 | 2024 | |
| Dexcom, INC. | $34.12 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $29.33 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $19.30 | 2023 | Belsomra |
| Vertex Pharmaceuticals Incorporated | $16.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Fleres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.